Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0IJ7O
|
||||
Former ID |
DNC000928
|
||||
Drug Name |
Metastat
|
||||
Drug Type |
Small molecular drug
|
||||
Structure |
Download2D MOL |
||||
Formula |
C19H17NO7
|
||||
CAS Number |
CAS 15866-90-7
|
||||
PubChem Compound ID | |||||
Target and Pathway | |||||
Target(s) | 72 kDa type IV collagenase | Target Info | Inhibitor | [535550] | |
PANTHER Pathway | Alzheimer disease-presenilin pathway | ||||
Pathway Interaction Database | LPA receptor mediated events | ||||
Plasma membrane estrogen receptor signaling | |||||
Osteopontin-mediated events | |||||
Validated transcriptional targets of AP1 family members Fra1 and Fra2 | |||||
Angiopoietin receptor Tie2-mediated signaling | |||||
Direct p53 effectors | |||||
amb2 Integrin signaling | |||||
ATF-2 transcription factor network | |||||
FOXM1 transcription factor network | |||||
Regulation of nuclear beta catenin signaling and target gene transcription | |||||
Syndecan-2-mediated signaling events | |||||
References | |||||
Ref 521425 | ClinicalTrials.gov (NCT00001683) A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer. U.S. National Institutes of Health. | ||||
Ref 527241 | A phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties. Clin Cancer Res. 2004 Oct 1;10(19):6512-21. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.